Which offers deserve a pause?

Is there a real prescription?

A prescription-only medicine cannot be dispensed lawfully without a valid prescription (federal position as of September 26, 2026).

Ask how the clinician assesses the problem and how follow-up questions reach them.

What does the official-looking claim prove?

In the US, the Food and Drug Administration is the regulator abbreviated FDA.

“Drug listing” means a medicine is entered in the FDA’s records. “Establishment registration” means a business is entered in those records. Neither means the agency has approved the medicine or the business (rule as of September 26, 2026).

An NDC, meaning a National Drug Code number, also does not prove product approval.

A compounded preparation described as FDA-approved is misrepresented; the September 26, 2026 rule review confirms that distinction.

What if the package says “for research use only”?

That wording describes a chemical for research, not a medicine supplied for your care. Buying it to inject is not a lawful way to obtain treatment.

In letters reviewed on September 26, 2026, the FDA told sellers that advertising these chemicals for human treatment still brings them under drug law. Writing “research use only” on the package does not remove those duties.

Getting a research chemical is different from having your prescription filled by a licensed pharmacy.

Ask for the pharmacy’s name and verify its record before treating an offer as care.

Can the appearance of a site settle it?

The Federal Trade Commission warns that a seal or refund promise on a health page can be a fake.

Ask for records you can check with the relevant board. A website’s appearance cannot tell you whether the people behind it can be trusted.